Assessment of ultra-pulse CO2 laser therapy in comparison to sequential laser and drug treatments for scar reduction

Scar management, particularly for early proliferative burn scars, remains a clinical challenge. This study assesses the efficacy of ultra-pulse carbon dioxide (CO2) laser therapy in comparison to sequential laser therapy and pharmacological interventions for scar reduction. A retrospective evaluation was conducted from January 2016 to March 2019 involving 200 patients with early proliferative burn scars treated at the Burn and Plastic Surgery Department of our institution. Participants were assigned to 4 groups: Group A received ultra-pulse CO2 laser therapy, Group B underwent sequential pulsed dye laser therapy, Group C received sequential laser therapy combined with pharmacological treatment, and a control group received no intervention. Clinical outcomes were assessed using the Vancouver Scar Scale (VSS) and the Numeric Pain Rating Scale. Efficacy was evaluated based on scar characteristics and pain scores. Demographic characteristics across all groups were comparable, with no significant differences noted (P > .05). The clinical efficacy assessment revealed that the overall effective rates for Group A, Group B, and Group C were 80.00%, 96.00%, and 98.00%, respectively. Groups B and C not only exhibited significantly higher effective rates but also demonstrated marked improvements in scar characteristics as measured by the VSS, including reduced erythema and thickness. Additionally, pain scores during treatment were lowest in Group C, indicating better tolerability compared to the other modalities (P < .05). Sequential laser therapy improves the clinical efficacy for early proliferative burn scars, enhancing scar characteristics overall. When combined with pretreatment pharmacotherapy, this approach also reduces patient pain during treatment. These results highlight the benefits of integrating sequential laser and drug therapies in scar management.